(PB)PK modellen van antikankergeneesmiddelen in kinderen met ALL, inclusief maturatie met behulp van longitudinale analyse.
Wat is het effect van CYP2A1 remming op de bijwerkingen van clozapine.
Bestudering van de post-mortale verdeling van geneesmiddelen.
Bestudering van de post-mortale verdeling van geneesmiddelen.
OSIBOOST 2 is a clinical trial designed to enhance the cost-effectiveness of Osimertinib for patients with Non-Small Cell Lung Cancer (NSCLC). Although Osimertinib significantly improves progression-free survival compared to older EGFRm-targeted therapies, its high cost remains a concern. To address this, the trial investigates the use of the CYP3A4 inhibitor Cobicistat, which reduces the metabolism of Osimertinib and increases its exposure (a process known as pharmacokinetic boosting). This approach allows patients to take a lower dose of Osimertinib while achieving the same therapeutic effect, potentially making the treatment more affordable without compromising its efficacy.
To demonstrate abnormalities in antibiotic pharmacokinetics and consequently antibiotic exposure in critically ill patients